--- title: "Dynavax Tech | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 94.88 M" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/264497561.md" datetime: "2025-11-05T21:12:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/264497561.md) - [en](https://longbridge.com/en/news/264497561.md) - [zh-HK](https://longbridge.com/zh-HK/news/264497561.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/264497561.md) | [English](https://longbridge.com/en/news/264497561.md) # Dynavax Tech | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 94.88 M Revenue: As of FY2025 Q3, the actual value is USD 94.88 M, beating the estimate of USD 94 M. EPS: As of FY2025 Q3, the actual value is USD 0.21, beating the estimate of USD 0.1167. EBIT: As of FY2025 Q3, the actual value is USD 16.32 M. ### Segment Revenue - **Total Revenues**: $94.876 million for the three months ended September 30, 2025, compared to $80.630 million for the same period in 2024, representing an 18% increase. For the nine months ended September 30, 2025, total revenues were $258.482 million, compared to $205.214 million for the same period in 2024, representing a 26% increase. - **HEPLISAV-B Product Revenue**: $89.954 million for the three months ended September 30, 2025, compared to $79.345 million for the same period in 2024, representing a 13% increase. For the nine months ended September 30, 2025, HEPLISAV-B product revenue was $246.785 million, compared to $197.377 million for the same period in 2024, representing a 25% increase. ### Operational Metrics - **Net Income (Loss)**: Net income of $26.927 million for the three months ended September 30, 2025, compared to $17.594 million for the same period in 2024. Net loss of $50.451 million for the nine months ended September 30, 2025, compared to net income of $20.259 million for the same period in 2024. - **Cost of Sales - Product**: $14.403 million for the three months ended September 30, 2025, compared to $13.084 million for the same period in 2024, representing a 10% increase. For the nine months ended September 30, 2025, cost of sales - product was $42.207 million, compared to $36.035 million for the same period in 2024, representing a 17% increase. - **Research and Development Expenses**: $19.116 million for the three months ended September 30, 2025, compared to $14.403 million for the same period in 2024, representing a 33% increase. For the nine months ended September 30, 2025, research and development expenses were $55.112 million, compared to $42.881 million for the same period in 2024, representing a 29% increase. - **Selling, General and Administrative Expenses**: $40.086 million for the three months ended September 30, 2025, compared to $43.061 million for the same period in 2024, representing a 7% decrease. For the nine months ended September 30, 2025, selling, general and administrative expenses were $138.123 million, compared to $128.788 million for the same period in 2024, representing a 7% increase. ### Cash Flow - **Net Cash Provided by Operating Activities**: $37.621 million for the nine months ended September 30, 2025, compared to $13.501 million for the same period in 2024. - **Net Cash Provided by (Used in) Investing Activities**: $129.025 million for the nine months ended September 30, 2025, compared to -$41.401 million for the same period in 2024. - **Net Cash Used in Financing Activities**: -$103.861 million for the nine months ended September 30, 2025, compared to -$3.142 million for the same period in 2024. ### Future Outlook and Strategy - **Core Business Focus**: Dynavax Technologies Corporation aims to maximize the utilization of HEPLISAV-B, expand its portfolio of innovative vaccine candidates leveraging its CpG 1018 adjuvant, and leverage its adjuvant supply strategy through commercial and research collaborations. - **Non-Core Business**: The company is advancing a pipeline of differentiated product candidates, including a shingles vaccine candidate and a plague vaccine candidate in collaboration with the U.S. Department of Defense. Additionally, Dynavax is working on a Lyme disease vaccine candidate and a pandemic influenza adjuvant program. ### 相關股票 - [Dynavax Tech (DVAX.US)](https://longbridge.com/zh-HK/quote/DVAX.US.md) ## 相關資訊與研究 - [Dynavox Group CFO to Step Down in Planned Transition by January 2027](https://longbridge.com/zh-HK/news/279902984.md) - [Dynavox Q4 revenue rises 16% to SEK 677 million](https://longbridge.com/zh-HK/news/274923640.md) - [Nike Takes 'Intentional' Hit To Clear 'Unhealthy Inventory' In Q3 As CEO Eyes Turnaround By Year-End](https://longbridge.com/zh-HK/news/281362844.md) - [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/zh-HK/news/281225115.md) - [Nike Delivers Q3 Earnings Beat As Turnaround Progresses, Shares Slide](https://longbridge.com/zh-HK/news/281243092.md)